EX-10.56



 Exhibit 10.56 

SECURITIES PURCHASE AGREEMENT 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 26, 2014, is by and among Alimera Sciences,
Inc. (the “Company”) and Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations Fund
International Master Fund, L.P. (collectively the “Investors”). 
 RECITALS 

WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) the Registration Statement (as
defined below) relating to the offer and sale from time to time of the Company’s securities, including shares of its common stock, par value $0.01 per share (the “Common Stock”) and shares of its preferred stock, par value
$0.01 per share (“Preferred Stock”); 
 WHEREAS, the Board of Directors of the Company has authorized the creation of a new
series of Preferred Stock denominated as Series B Convertible Preferred Stock (“Series B Preferred Stock”); 
 WHEREAS, the
Company is offering for sale shares of Series B Preferred Stock and the Conversion Shares (as defined below) pursuant to the Registration Statement; 

WHEREAS, the Investors desire to purchase from the Company shares of Series B Preferred Stock on the terms and conditions set forth herein.

 NOW, THEREFORE, in consideration of the foregoing recitals (which are deemed to be a part of this Agreement), mutual covenants,
representations, warranties and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Definitions. As used herein, the following terms have the meanings indicated: 

“Aggregate Purchase Price” shall have the meaning set forth in Section 2(a) hereof. 

“Business Day” means any day other than Saturday, Sunday or a day on which banks in the City of New York are authorized or
required to be closed. 
 “Certificate of Designation” means the Certificate of Designation of Preferences, Rights and
Limitations of the Series B Convertible Preferred Stock, in the form attached hereto as Exhibit A. 
 “Common Stock
Equivalents” shall mean any securities of the Company which would entitle the holder thereof to acquire, directly or indirectly, at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants
or other 







 
instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock or other securities that entitle the holder to receive,
directly or indirectly, Common Stock. 
 “Conversion Shares” shall mean shares of Common Stock issuable upon conversion of
Series B Preferred Stock. 
 “Investor Shares” means 8,416.252 shares of Series B Preferred Stock. 

“knowledge” means with respect to any statement made to the Company’s knowledge, that statement is based upon the actual
knowledge of the Company or its Chief Executive Officer or Chief Operating Officer and Chief Financial Officer. 
 “Loss”
shall have the meaning set forth in Section 5 hereof. 
 “Material Adverse Effect” shall mean a material
adverse effect on (a) the business, operations, financial condition or assets of the Company or its subsidiaries taken as a whole, (b) the validity or enforceability of any provision of this Agreement, or (c) the rights and remedies
of the Investors under this Agreement. 
 “Person” shall mean any individual, partnership, limited liability company, joint
venture, firm, corporation, association, trust or other enterprise or any government or political subdivision or any agency, department or instrumentality thereof. 

“Principal Trading Market” shall mean whichever of the New York Stock Exchange, the NYSE Alternext (formerly the
American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 

“Prospectus” shall have the meaning set forth in Section 4(b)(7) hereof. 

“Prospectus Supplement” shall mean the prospectus supplement to be filed with the Commission regarding the Investor Shares
and the Conversion Shares pursuant to Rule 424(b) promulgated under the Securities Act (“Rule 424(b)”) and deemed to be part of the Registration Statement at the time of effectiveness. 

“Registration Statement” shall mean the registration statement on Form S-3 (File
No. 333-198044), including a prospectus, and including all amendments and supplements thereto (including the Prospectus Supplement), relating to the offer and sale of certain of the Company’s Common Stock, Preferred Stock, Debt Securities
and Warrants, including the Investor Shares and the Conversion Shares. References herein to the term “Registration Statement” as of any date shall mean such effective registration statement, as amended or supplemented to such date,
including all information and documents incorporated by reference therein as of such date. 
 “Securities Act” shall mean
the Securities Act of 1933, as amended. 

  
 2 








 2. Purchase of Series B Preferred Stock. 

(a) Subject and pursuant to the terms and conditions set forth in this Agreement, the Company agrees that it will issue and sell to the
Investors, and the Investors agree that they will purchase from the Company, the number of Investor Shares set forth after their name on Schedule 1 attached hereto in the column headed “Number of Shares of Series B Preferred Stock
to be Purchased by Investor Pursuant to Section 2(a)” at a purchase price of $6,030 for each Investor Share and an aggregate purchase price of $50,000,000 (the “Aggregate Purchase Price”). The closing of the purchase and
sale of the Investor Shares will take place not more than fifteen (15) Business Days following the date of this Agreement, or such other date or time as the parties may agree upon in writing (the “Closing”). 

(b) At the Closing, the Investors shall be entitled to receive a subscription premium equal to 1.5% of the Aggregate Purchase Price which
shall be payable by the issuance of additional Investor Shares as set forth on Schedule 1 hereto. 
 3. Deliveries at Closing. 

(a) Deliveries by the Investor. At the Closing, each Investor shall deliver to the Company the Aggregate Purchase Price set forth next
to its name on Schedule 1 hereto by wire transfer of immediately available funds to a bank account designated in writing by the Company to the Investors, which funds will be delivered to the Company in consideration of the Investor Shares
issued at the Closing. 
 (b) Deliveries by the Company. At the Closing, the Company shall 

(1) deliver to each Investor stock certificates in a form, reasonably satisfactory to the Investors, registered in the name of such Investor
evidencing the number of shares of Series B Preferred Stock issuable to such Investor; and 
 (2) deliver evidence satisfactory to the
Investors, that the Certificate of Designation has been filed with the Secretary of State of Delaware and has become effective on or prior to the Closing. 

4. Representations, Warranties, Covenants and Agreements. 

(a) Investor Representations, Warranties and Covenants. Each Investor represents, warrants, covenants and agrees as follows as of the
date hereof and as of the Closing: 
 (1) Investor has received and reviewed copies of the Registration Statement and the Prospectus,
including all documents and information incorporated by reference therein and amendments thereto, and understands that no Person has been authorized to give any information or to make any representations that were not contained in the Registration
Statement and the Prospectus, and Investor has not relied on any such other information or representations in making a decision to acquire the Investor Shares. Investor hereby consents to receiving delivery of the Registration Statement and the
Prospectus, including all documents and information incorporated by reference therein and amendments thereto, by electronic mail or by 

  
 3 








 
accessing the EDGAR database on the Commission’s website. Investor understands that an investment in the Company involves a high degree of risk for the reasons, among others, set forth under
the caption “Risk Factors” in the Prospectus. 
 (2) Investor acknowledges that it has sole responsibility for its own due
diligence investigation and its own investment decision, and that in connection with its investigation of the accuracy of the information contained or incorporated by reference in the Registration Statement and the Prospectus and its investment
decision, Investor has not relied on any representation or information, as the case may be, not set forth in this Agreement, the Registration Statement or the Prospectus, or any Person affiliated with the Company or on the fact that any other Person
has decided to purchase the Investor Shares. 
 (3) The execution and delivery of this Agreement by Investor and the performance of this
Agreement and the consummation by Investor of the transactions contemplated hereby have been duly authorized by all necessary corporate or partnership action of Investor, as applicable, and this Agreement, when duly executed and delivered by
Investor, will constitute a valid and legally binding instrument, enforceable in accordance with its terms against Investor, except as enforcement hereof may be limited by the effect of any applicable bankruptcy, insolvency, reorganization or
similar laws or court decisions affecting enforcement of creditors’ rights generally and except as enforcement hereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at
law). 
 (b) Company Representations, Warranties and Covenants. The Company hereby represents, warrants, covenants and agrees as
follows as of the date hereof and as of the Closing: 
 (1) The Company has been duly incorporated and is validly existing as a corporation
under the laws of the State of Delaware, with corporate power and authority to own its properties and conduct its business as described in the Prospectus, and has been duly qualified as a foreign corporation for the transaction of business and is in
good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except for such jurisdictions wherein the failure to be so qualified and in good standing
would not individually or in the aggregate have a Material Adverse Effect. 
 (2) Each subsidiary of the Company has been duly incorporated
or organized and is validly existing in good standing (to the extent the concept of good standing exists in the subsidiary’s jurisdiction or incorporation or organization) under the laws of its jurisdiction of incorporation or organization,
with power and authority to own its properties and conduct its business as described in the Prospectus, and has been duly qualified for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or
leases properties or conducts any business so as to require such qualification, except for such jurisdictions wherein the failure to be so qualified and in good standing would not individually or in the aggregate have a Material Adverse Effect.
Except as disclosed by the Company’s periodic reports filed with the Commission and except as required pursuant to this Agreement and as of the date of the most recent quarterly report filed by the Company, there are no outstanding
(i) securities of the Company or any of the subsidiaries of the Company which are convertible into or exchangeable for shares of capital stock or voting securities of any subsidiary of the Company or (ii) options or other rights to acquire
from the Company or any subsidiary of 

  
 4 








 
the Company, or other obligation of the Company or any subsidiary of the Company to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or
voting securities of any subsidiary of the Company (collectively, the “Subsidiary Securities”). There are no outstanding obligations of the Company or any subsidiary of the Company to repurchase, redeem or otherwise acquire any
outstanding Subsidiary Securities. 
 (3) The execution, delivery and performance of this Agreement by the Company and the consummation of
the transactions contemplated hereby are within the corporate powers of the Company and have been duly authorized by all necessary corporate action on the part of the Company and this Agreement, when duly executed and delivered by the parties
hereto, will constitute a valid and legally binding instrument of the Company enforceable in accordance with its terms, except as enforcement hereof may be limited by the effect of any applicable bankruptcy, insolvency, reorganization or similar
laws or court decisions affecting enforcement of creditors’ rights generally and except as enforcement hereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law). 

(4) The Investor Shares have been duly authorized by the Company, and when issued and delivered by the Company against payment therefor as
contemplated by this Agreement will be validly issued, fully paid and nonassessable, and will conform to the description of the Series B Preferred Stock contained in the Prospectus. The Investor Shares and the Conversion Shares will be issued in
compliance with all federal and state securities laws. 
 (5) The Company has reserved from its duly authorized capital stock a number of
shares of Common Stock sufficient for issuance of all of the Conversion Shares. The Conversion Shares, when issued, will have been duly authorized and, when issued, delivered and paid for in accordance with the terms of the Certificate of
Designation, will have been validly issued and will be fully paid and nonassessable. The Company shall, so long as any of the Series B Preferred Stock is outstanding, take all action necessary to reserve and keep available out of its authorized and
unissued capital stock, solely for the purpose of effecting the conversion of the Series B Preferred Stock, the number of shares of Common Stock issuable upon such conversion (without taking into account any limitations on the conversion of the
Series B Preferred Stock set in the Certificate of Designation). 
 (6) The execution and delivery of this Agreement do not, and the
compliance by the Company with the terms hereof will not, (i) violate the Certificate of Incorporation (as amended to date) of the Company or the By-Laws (as amended to date) of the Company,
(ii) result in a breach or violation of any of the terms or provisions of, or constitute a material default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of their properties or assets are subject, or (iii) result in a violation of, or failure to be in compliance with, any applicable statute or any
order, judgment, decree, rule or regulation of any court or governmental, regulatory or self-regulatory agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties or assets, except where such breach,
violation, default or the failure to be in compliance would not individually or in the aggregate have a Material Adverse Effect or adversely affect the ability of the Company to issue and sell the Investor Shares; and no consent,


  
 5 








 
approval, authorization, order, registration, filing or qualification of or with any such court or governmental, regulatory or self-regulatory agency or body is required for the valid
authorization, execution, delivery and performance by the Company of this Agreement or the issuance of the Investor Shares, except for the filing of one or more Form 8-Ks, the filing of the Prospectus Supplement, the filing of the Certificate of
Designation (which is required to be filed and effective prior to the Closing in accordance with Section 3(b)(2) hereof), the filing of a Notification of Listing of Additional Shares with The NASDAQ Stock Market LLC, and for such consents,
approvals, authorizations, registrations, filings or qualifications as may be required under state securities or “blue sky” laws. 

(7) The Company meets the requirements for use of Form S-3 under the Securities Act. The Registration Statement, which covers the Investor
Shares and the Conversion Shares, including a form of prospectus and such amendments or supplements to such Registration Statement as may have been required prior to the date of this Agreement, has been prepared by the Company under the provisions
of the Securities Act, has been filed with the Commission, has become effective and filed with the Commission and incorporates by reference documents which the Company has filed in accordance with the provisions of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). The Company has prepared a Prospectus Supplement to the prospectus included in the Registration Statement referred to above, setting forth the terms of the offering and sale of the Investor
Shares and additional information concerning the Company and its business and will promptly file the Prospectus Supplement with the Commission pursuant to Rule 424(b). No stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto, or any part thereof, has been issued and served on the Company, and no proceedings for that purpose are pending or, to the knowledge of the Company, threatened by the Commission. The form of prospectus included in
the Registration Statement as of the date hereof, as amended or supplemented from time to time (including the Prospectus Supplement), is referred to herein as the “Prospectus.” Any reference herein to the Registration Statement, the
Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated (or deemed to be incorporated) by reference therein, and any reference herein to the terms “amend,” “amendment”
or “supplement” with respect to the Registration Statement or Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein. As
of the close of business on November 26, 2014, at least a number of shares of Preferred Stock and Common Stock equal to the number of Investor Shares and Conversion Shares, respectively, were available for issuance pursuant to the Registration
Statement, which permits the issuance of the Investor Shares and the Conversion Shares in the manner contemplated by this Agreement. 
 Each
part of the Registration Statement, when such part became or becomes effective, and the Prospectus and any amendment or supplement thereto, on the date of filing thereof with the Commission and at the date hereof and the date of the Closing, did or
will in all material respects comply with all applicable provisions of the Securities Act and the Exchange Act. Each part of the Registration Statement, when such part became or becomes effective, did not or will not contain any untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading. The Prospectus and any amendment or supplement thereto, on the date of filing thereof with the
Commission, did not or will not contain any untrue statement of a material fact or omit to state a 

  
 6 








 
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and any statutes, regulations, contracts or other documents
that are required to be described in the Registration Statement or Prospectus or to be filed as exhibits to the Registration Statement have been so described or filed. 

(8) The consolidated financial statements and financial schedules of the Company included or incorporated by reference in the Registration
Statement and the Prospectus have been prepared in conformity with generally accepted accounting principles (except, with respect to the unaudited consolidated financial statements, for the footnotes and subject to customary audit adjustments)
applied on a consistent basis, are consistent in all material respects with the books and records of the Company, and accurately present in all material respects the consolidated financial position, results of operations and cash flow of the Company
and its subsidiaries as of and for the periods covered thereby. 
 (9) Neither the Company nor any of its subsidiaries has sustained since
the respective dates of the latest audited financial statements included or incorporated by reference in the Registration Statement and Prospectus any material loss or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as disclosed in or contemplated by the Registration Statement and Prospectus; and, since the respective dates as of which
information is given in the Registration Statement and Prospectus, other than as contemplated in this Agreement, there has not been any material change in the capital stock or long-term debt of the Company or any of its subsidiaries. 

(10) Other than as disclosed in the Prospectus, there are no legal, governmental or regulatory proceedings pending to which the Company or
any of its subsidiaries is a party or of which any material property of the Company or any of its subsidiaries is the subject which, taking into account the likelihood of the outcome, the damages or other relief sought and other relevant factors,
would individually or in the aggregate reasonably be expected to have a Material Adverse Effect or adversely affect the ability of the Company to issue and sell the Investor Shares, and no such proceedings are threatened in writing to the Company
or, to the Company’s knowledge, have been contemplated by governmental or regulatory authorities or threatened by others. 
 (11) The
Company and each of its subsidiaries have title to all the real property, and owns all other properties and assets, reflected as owned in the financial statements included or incorporated by reference in the Registration Statement and the
Prospectus, subject to no lien, mortgage, pledge, charge or encumbrance of any kind except those, if any, reflected in such financial statements or disclosed in the Company’s filings with the Commission or exhibits thereto, or which are not
material to the Company and its subsidiaries taken as a whole. The Company and each of its subsidiaries hold their respective leased real and personal properties under valid and binding leases, except where the failure to do so would not reasonably
be expected to individually or in the aggregate have a Material Adverse Effect. 
 (12) The Company has filed all necessary federal and
state income and franchise tax returns and has paid all taxes shown as due thereon or has filed all necessary extensions, and there is no tax deficiency that has been, or to the knowledge of the Company


  
 7 








 
could reasonably be expected to be, asserted against the Company or any of its properties or assets that would in the aggregate or individually reasonably be expected to have a Material Adverse
Affect. 
 (13) There are no holders of securities of the Company having preemptive rights to purchase Common Stock. There are no holders
or beneficial owners of securities of the Company having rights to registration thereof whose securities have not been previously registered or who have not waived such rights with respect to the registration of the Company’s securities on the
Registration Statement, except where the failure to obtain such waiver would not individually or in the aggregate reasonably be expected to have a Material Adverse Effect. 

(14) The issuance of the Investor Shares and the Conversion Shares will not obligate the Company to issue shares of Common Stock or other
Common Stock Equivalents to any Person (other than the Investors), will not trigger any preemptive or other rights to subscribe for or purchase securities and will not result in a right of any holder of Company securities to adjust the exercise,
conversion, exchange or reset price or other right under any of such securities. 
 (15) The Company is not, and does not intend to conduct
its business in a manner in which it would become, an “investment company” as defined in Section 3(a) of the Investment Company Act of 1940, as amended. 

(16) The Company is in compliance in all material respects with all listing and maintenance requirements of the Principal Trading Market. The
issuance and sale of the Investor Shares and the issuance of the Conversion Shares will, at the time of such issuance and sale, comply in all material respects with and will not contravene the rules and regulations of the Principal Trading Market.
The Conversion Shares, when issued, will be listed for trading on the Principal Trading Market. 
 5. Indemnification. 

(a) Subject to the limitations and other provisions of this Section 5, the Company covenants and agrees to indemnify, defend and
hold harmless the Investors and their respective directors, officers, partners, managers, employees and agents (each, an “Investor Party”) from and against any and all Losses arising from claims by third parties resulting from,
incurred in connection with or arising out of (but only to the extent of) (a) any breach of any representation, warranty or covenant of the Company contained herein, or (b) the failure of the Company to perform any of the agreements,
covenants or obligations contained herein (other than if any such claim was a result of a breach by the Investor hereunder). Subject to the limitations and other provisions of this Section 5, the Investor covenants and agrees to
indemnify, defend and hold harmless the Company from and against (but only to the extent of) any and all Losses arising from claims by third parties resulting from, incurred in connection with or arising out of (but only to the extent of)
(a) any breach of any representation or warranty of the Investor contained herein, or (b) the failure of the Investor to perform any of the agreements, covenants or obligations of the Investor contained herein. The term
“Loss” or any similar term shall mean any and all damages, deficiencies, costs, claims, fines, judgments, amounts paid in settlement, 

  
 8 








 
expenses of investigation, interest, penalties, taxes, assessments, out-of-pocket expenses (including reasonable attorneys’ and auditors’ fees and disbursements, witness fees and court
costs) but specifically excluding consequential, special, punitive, multiple and other similar damages. The party or parties being indemnified are referred to herein as the “Indemnitee” and the indemnifying party is referred to
herein as the “Indemnitor.” 
 (b) Indemnification Procedure. 

(1) Any party who receives notice of a potential claim that may, in the judgment of such party, result in a Loss shall use all reasonable
efforts to provide the parties hereto notice thereof within fifteen (15) days of the filing or other written assertion of any such claim against the Indemnitee, provided that failure or delay or alleged delay in providing such notice shall not
adversely affect such party’s right to indemnification hereunder, unless and then only to the extent that such failure or delay or alleged delay has resulted in actual prejudice to the Indemnitor, including, without limitation, by the
expiration of a statute of limitations. In the event that any party shall incur or suffer any Losses in respect of which indemnification may be sought by such party hereunder, the Indemnitee shall assert a claim for indemnification by written notice
(a “Notice”) to the Indemnitor stating the nature and basis of such claim. 
 (2) In the case of third party claims for
which indemnification is sought, the Indemnitor shall, if necessary, retain counsel reasonably satisfactory to the Indemnitee, and have the option (i) to conduct any proceedings or negotiations in connection therewith, (ii) to take all
other steps to settle or defend any such claim (provided that the Indemnitor shall not settle any such claim without the consent of the Indemnitee which consent shall not be unreasonably withheld or delayed) and (iii) to employ counsel to
contest any such claim or liability in the name of the Indemnitee or otherwise. In any event, the Indemnitee shall be entitled to participate at its own expense and by its own counsel in any proceedings relating to any third party claim. The
Indemnitor shall, within fifteen (15) Business Days of receipt of the Notice, notify the Indemnitee of its intention to assume the defense of such claim. If (i) the Indemnitor shall decline to assume the defense of any such claim,
(ii) the Indemnitor shall fail to notify the Indemnitee within fifteen (15) Business Days after receipt of the Notice of the Indemnitor’s election to defend such claim or (iii) in the reasonable opinion of counsel for the
Indemnitee, the representation by the same counsel of the Indemnitor and the Indemnitee would be inappropriate due to actual or potential material differing interests between such Indemnitee and any other party represented by such counsel in such
proceeding, then in each such case the Indemnitor shall not have the right to direct the defense of such action on behalf of the Indemnitee and the Indemnitee shall, at the sole expense of the Indemnitor, defend against such claim; provided,
that the Indemnitee may not settle such claim without the consent of the Indemnitor (which consent will not be unreasonably withheld or delayed). In such event, the Indemnitor shall pay for only one separate legal counsel for the Indemnitees, and
such legal counsel shall be selected by the Indemnitee. The reasonable expenses of all proceedings, contests or lawsuits in respect of such claims shall be borne and paid by the Indemnitor if the Indemnitee is entitled to indemnification hereunder
and the Indemnitor shall pay the Indemnitee, in immediately available funds, the amount of any Losses, within a reasonable time of the incurrence of such Losses. Regardless of which party shall assume the defense or negotiation of the settlement of
the claim, the parties agree to cooperate fully with one another in connection therewith. Anything in this Section 5 to the contrary notwithstanding, the Indemnitor shall not, 

  
 9 








 
without the Indemnitee’s prior written consent, settle or compromise any claim or consent to entry of any judgment in respect thereof which imposes any future obligation on the Indemnitee or
which does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to the Indemnitee, a release from all liability in respect of such claim. 

(c) No Waiver. Nothing herein shall in any way limit a Party’s remedies in respect of a breach of any representation, warranty or
covenant hereunder. 
 6. Conditions. 

(a) The obligation of each Investor to purchase and acquire the Investor Shares hereunder shall be subject to the conditions that: 

(1) All representations and warranties of the Company herein shall be true and correct in all material respects as of and on each of the date
of this Agreement and the date of the Closing; 
 (2) The Company shall have performed all of its obligations hereunder; including delivery
of certificates for the Series B Preferred Stock; 
 (3) The Prospectus Supplement shall have been filed with the Commission pursuant to
Rule 424(b) within the applicable time period prescribed for such filing, no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been
initiated or threatened by the Commission, and the Investor shall have received the Prospectus in accordance with the federal securities laws. 

(b) The obligation of the Company to sell the Investor Shares hereunder shall be subject to the conditions that: 

(1) All representations and warranties and other statements of the Investors herein shall be true and correct in all material respects as of
and on each of the date of this Agreement and the date of the Closing; 
 (2) The Investors shall have performed all of their obligations
hereunder. 
 7. Covenants. 

(a) Fees and Costs. The Company will reimburse the Investors for reasonable, documented expenses for attorneys, accountants and other
professional advisors, and other out-of-pocket expenses incurred by Investors in connection with their due diligence, negotiation and documentation of the transactions contemplated up to an aggregate amount of $200,000. 

(b) The Company shall, so long as any of the Investor Shares is outstanding, take all action necessary to reserve and keep available out of
its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Investor Shares, the number of 

  
 10 








 
shares of Common Stock issuable upon such conversion (without taking into account any limitations on the conversion of the Series B Preferred Stock set forth in the Certificate of Designation),
free and clear of all encumbrances and restrictions. The Company shall cause the Conversion Shares, when issued in accordance with the provisions of the Certificate of Designation, to be duly authorized, validly issued and fully paid and
non-assessable. 
 8. Miscellaneous. 

(a) Binding Agreement; Assignment. This Agreement shall be binding upon, and shall inure solely to the benefit of, each of the parties
hereto, and each of their respective heirs, executors, administrators, successors and assigns, and no other person other than Indemnitees shall acquire or have any right under or by virtue of this Agreement. The Company may not assign any of its
rights or obligations hereunder to any other person or entity without the prior written consent of the Investors. 
 (b) Entire
Agreement. This Agreement and the Certificate of Designation, including the Schedules and Exhibits hereto constitute the entire understanding between the parties hereto with respect to the subject matter hereof and may be amended only by written
execution by both parties. Upon execution by the Company and the Investors, this Agreement shall be binding on each of the parties hereto. 

(c) Consent To Jurisdiction. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED AND CONSTRUED IN ALL RESPECTS IN ACCORDANCE WITH THE LAWS OF
THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ITS CONFLICTS OF LAWS PRINCIPLES OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF SUCH STATE. FURTHERMORE, THE INVESTOR HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE
FEDERAL OR STATE COURTS LOCATED IN THE STATE OF NEW YORK IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE COMPANY AND THE INVESTORS (AND, TO THE EXTENT PERMITTED BY LAW, ON
BEHALF OF ITS AND THEIR EQUITY HOLDERS AND CREDITORS) HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE
TRANSACTIONS CONTEMPLATED HEREBY. 
 (d) Notices. Any notice, request or other communication to be given or made under this Agreement
shall be in writing. Such notice, request or other communication shall be deemed to have been duly given or made when it shall be delivered by hand, overnight mail, international courier (confirmed by facsimile), electronic mail or facsimile to the
Party to which it is required or permitted to be given or made at such Party’s address specified below or at such other address as such Party shall have designated by notice to the other Parties. 

If to the Borrower: 
 Alimera
Sciences, Inc. 
 6210 Windward Parkway, Suite 290 

Alpharetta, GA 30005 
 E-mail:
rick.eiswirth@alimerasciences.com 
 Attention: Richard S. Eiswirth, Jr., Chief Financial Officer and Chief Operating Officer 

  
 11 








 With a copy to: 

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 

One Marina Park Drive, Suite 900 

Boston, MA 02210 
 Fax:
(617) 648-9199 
 Email: ggriner@gunder.com 

Attn: Gregg A. Griner, Esq. 
 If
to the Purchasers: 
 Deerfield Management Company, L.P. 

780 Third Avenue, 37th Floor 
 New
York, NY 10017 
 Fax: (212) 599-3075 

Email: dclark@deerfield.com 

Attn: David J. Clark 
 With a copy
to: 
 Katten Muchin Rosenman LLP 

575 Madison Avenue 
 New York, New
York 10022 
 Fax: (212) 940-8776 

Email: mark.fisher@kattenlaw.com 

Attn: Mark I. Fisher, Esq. 
 or to such other
Person at such other place as the parties shall designate to one another in writing. 
 (e) Counterparts. This Agreement maybe
executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one in the same agreement. 

(f) Telecopy Execution and Delivery. A facsimile, electronic mail, telecopy, PDF or other reproduction of this Agreement may be
executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties by facsimile, e-mail or similar electronic transmission device pursuant to which the signature of or on behalf of such party can
be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party, all parties agree to execute an original of 

  
 12 








 
this Agreement as well as any facsimile, telecopy or reproduction thereof. The parties hereto hereby agree that neither shall raise the execution of facsimile, telecopy, PDF or other reproduction
of this Agreement, or the fact that any signature or document was transmitted or communicated by facsimile, e-mail or similar electronic transmission device, as a defense to the formation of this Agreement. 

[Signature pages follow] 

  
 13 








 IN WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly
executed as of the 26th day of November, 2014. 
  

			
	COMPANY:
	
	ALIMERA SCIENCES, INC.
		
	By:	 	 /s/ Richard S. Eiswirth, Jr.

	Name:	 	Richard S. Eiswirth, Jr.
	Title:	 	Chief Operating Officer and Chief Financial Officer
	
	INVESTORS:
	
	DEERFIELD PRIVATE DESIGN FUND II, L.P.
		
	By:	 	Deerfield Mgmt., L.P., General Partner
	By:	 	J.E. Flynn Capital, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
		
	By:	 	Deerfield Mgmt., L.P., General Partner
	By:	 	J.E. Flynn Capital, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
		
	By:	 	Deerfield Mgmt., L.P., General Partner
	By:	 	J.E. Flynn Capital, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 [Signature Page to Securities Purchase Agreement] 








			
	DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
		
	By:	 	Deerfield Mgmt., L.P., General Partner
	By:	 	J.E. Flynn Capital, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	DEERFIELD PRIVATE DESIGN FUND III, L.P.
		
	By:	 	Deerfield Mgmt. III, L.P., General Partner
	By:	 	J.E. Flynn Capital III, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 [Signature Page to Securities Purchase Agreement] 







 Schedule 1 

 

					
	 Purchase Price Per Share of Series B Preferred Stock
	  	$	6,030	  

  

																	
	 Name of Investor
	  	Aggregate
Purchase Price	 	  	Number
of Shares of
Series B
Preferred
Stock
to be
Purchased
by Investor
Pursuant
to
Section 2(a)*	 	 	Number
of Shares of
Series B
Preferred
Stock
to be
Issued to
Investor
Pursuant
to
Section 2(b)*	 	  	Total
Investor
Shares*	 
					
	 Deerfield Private Design Fund II, L.P.
	  	$	10,485,000	  	  	 	1,738.806	  	 	 	26.082	  	  	 	1,764.886	  
					
	 Deerfield Private Design International II, L.P.
	  	$	12,015,000	  	  	 	1,992.537	  	 	 	29.888	  	  	 	2,002.425	  
					
	 Deerfield Private Design Fund III, L.P.
	  	$	22,500,000	  	  	 	3,731.343	  	 	 	55.970	  	  	 	3,787.313	  
					
	 Deerfield Special Situations Fund, L.P.
	  	$	2,730,000	  	  	 	452.736	  	 	 	6.791	  	  	 	459.527	  
					
	 Deerfield Special Situations Fund International Limited
	  	$	2,270,000	  	  	 	376.451	  	 	 	5.647	  	  	 	382.098	  
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 
					
	 Total:
	  	$	50,000,000	  	  	 	8,291.873	* 	 	 	124.378	  	  	 	8,416.252	  

  

	*	Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock. 








 Exhibit A 

[Certificate of Designation]